This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology of dysthyroid eye disease

Authoring team

  • clinically evident in 25-50% of patients with Graves' hyperthyroidism - occurs occasionally in patients with Hashimoto's thyroiditis and in those with Graves' disease but no evident thyroid disease.

  • the mean age is 45 years and the female:male ratio is 2:1

  • there is an association with cigarette smoking, as 90% of cases occur in smokers

  • return to normal thyroid function is associated with improvement in the eye disease

  • association with HLA-DR3

  • Graves' hyperthyroidism and Graves' ophthalmology are overlapping, if not concurrent, conditions - many patients with Graves' hyperthyroidism but no clinical eye features can be shown to have evidence of ophthalmological changes with techniques such as orbital MRI - similarly many euthyroid patients with Graves' ophthalmology can be shown to have laboratory evidence of thyroid autoimmune disease.

  • in 85% of patients affected by either Graves' hyperthyroidism or Graves' ophthalmology, the other develops within 18 months.

Reference:

  • 1) Shine B et al (1990).Association between Graves' ophthalmology and cigarette smoking. Lancet, 335, 1261-3.
  • 2) Tallstedt L et al (1992).Occurence of ophthalmology after treatment of Graves' hyperthyroidism.NEJM, 326, 1733-8.
  • 3) Epstein FH (1993).Pathogenesis of Grave's ophthalmology. NEJM, 329(20),1468-75.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.